Ustekinumab conditional exposure and PASI turnover

Published parameter set 1 — exploratory 90 mg calendar

Deterministic fixed-parameter exploration with explicitly authored administrations and initial conditions.

Readouts

Central concentration · mg/L

Conditional model quantity; exposure and elimination integrals are added nonfeedback accounting readouts.

PASI score · dimensionless

PASI score over the selected simulation window.

PASI reduction fraction · dimensionless

PASI reduction fraction over the selected simulation window.

Mean central concentration · mg/L

Nonfeedback clock or exposure readout.

Accounted amount · mg

Conditional model quantity; exposure and elimination integrals are added nonfeedback accounting readouts.

Study purpose

• How do the model's key biological readouts change under published parameter set 1 — exploratory 90 mg calendar?

Assumptions

• Published individual conditional means define frozen parameter-set explorations; trajectories evaluated at these means generally differ from posterior-mean responses.
• PK amounts start drug-free and PASI starts at the published predicted baseline. kin=kout times baseline is a declared drug-free-equilibrium closure.
• The authored calendar uses90mg SC on days0,28,112 then every56days through560, with a predose endpoint at616days. Original individual treatment histories are unavailable.
• Published means already reflect their covariates; no additional body-weight scaling is applied.
• F is converted from percent to fraction once, with administered depot and complementary non-systemic loss explicitly distinguished.
• Parameter editing is held within each context because baseline changes require matching PASI initialization.
• No posterior clone generation, response probability, successful personalized regimen, original patient-trajectory or clinical dosing claim is made.